In Vitro, Ex Vivo and in Models to Develop New Therapies for Renal Diseases Frederick W. K. Tam, Imperial College London, speaking at ADME & Predictive Toxicology Europe 2012
Biotransformation: Still a Bottleneck for in Vitro Kinetic and Dynamic Approaches Sandra Coecke, European Centre for the Validation of Alternative Methods, speaking at ADME & Predictive Toxicology Europe
In Silico Toxicology: Where are We at and Where are We Going? John C. Dearden, Liverpool John Moores University, speaking at ADME & Predictive Toxicology Europe 2012
Outsourcing Chemical Synthesis in the Drug Discovery Process Gunter Festel, Autodisplay Biotech, speaking at Discovery Chemistry Congress 2012
When is a Genotoxin not a Genotoxin? Richard Walmsley, University of Manchester, speaking at ADME & Predictive Toxicology Europe
miRNA Replacement Therapy in Cancer through Polyplex-Mediated miRNA Delivery In Vivo Professor Achim Aigner, Institute of Pharmacology / bpc, Philipps-University Marburg, speaking at RNAi Europe 2011.
EU Regulatory Landscape for Approval of Biosimilars Dr Lincoln Tsang, Arnold and Porter LLP, speaking at BioProcessing, Biologics & Biotherapeutics Congress / Stem Cells Europe 2011.
Biotests for Hazard Characterization of Waste Dr Reinhilde Weltens, Vito, speaking at Advances in Biosensors and Biodetection.
Drug Discovery Outsourcing: the Importance of Integration in the Selection of Higher Quality Clinical Candidates Simone Braggio, Director, Head of Drug Metabolism & Pharmacokinetics, Aptuit speaking at Pharma Outsourcing Congress 2011